EQNR372.90-4.60%
DNB307.70+0.26%
MOWI201.20-1.57%
YARA424.80-2.97%
TEL135.00-0.15%
Brent$79.24-2.61%
DIREKTE · 17:12 UTC
Selskaper

Health Care — Alle selskaper

Full analysedekning av selskaper innen health care. Tilbake til oversikten for Health Care →
Full analysedekning 2997 companies · showing 2101–2250
Sorter etter
BSXASX

Blackstone Minerals Ltd

Advanced Medical Equipment & Technology
KursA$0.04
Børsverdi
P/E
OmsetningA$1,2 mill.
Driftsresultat-A$8,9 mill.
FCF-A$9,2 mill.

Blackstone Minerals Ltd has a negative return on equity of -11.56% and a negative return on assets of -11.63%, indicating poor capital efficiency and asset utilization. The company's liquidity posi…

Dilution: Low · Liquidity: Medium
CENGBursa Malaysia

Cengild Medical Bhd

Healthcare Facilities & Services
Kurs$0.20
Børsverdi
P/E
Omsetning$17,1 mill.
Driftsresultat$4,9 mill.
FCF$34,0k

Cengild Medical Bhd maintains a strong liquidity position, with a current ratio of 8.08, indicating a substantial buffer of current assets over current liabilities. However, the company reported ne…

Dilution: Low · Liquidity: Medium
CHHBBursa Malaysia

Chhb.Kl

Healthcare Facilities & Services
Kurs$0.15
Børsverdi
P/E
Omsetning$68,9 mill.
Driftsresultat-$30,8 mill.
FCF

CHHB.KL's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative approach to leverage. However, the company's liquidity is rated as medium, and its curr…

Dilution: Low · Liquidity: Medium
EHSI.PKOTC

Ehsi.Pk

Healthcare Providers & Services
Kurs$0.99
Børsverdi
P/E
Omsetning$1,0 mill.
Driftsresultat-$7,8 mill.
FCF-$8,8 mill.

EHSI.PK exhibits a strong liquidity position, with a current ratio of 3.35, indicating that the company has more than three times the current assets to cover its current liabilities. The company ho…

Dilution: Low · Liquidity: Low
GWLL.PKOTC

Goldenwell Biotech Inc

Biotechnology & Life-Science Tools
Kurs$0.90
Børsverdi
P/E
Omsetning
Driftsresultat-$19,7k
FCF-$21,3k

Goldenwell Biotech Inc has a current liquidity position characterized by a current ratio of 119.42, indicating strong short-term liquidity. The company has no long-term debt, and its debt-to-equity…

Dilution: Low · Liquidity: Low
HLYK.PKOTC

Hlyk.Pk

Healthcare Providers & Services
Kurs$2.95
Børsverdi
P/E
Omsetning$2,1 mill.
Driftsresultat-$1,8 mill.
FCF-$3,2 mill.

HLYK.PK exhibits a highly leveraged capital structure, with total liabilities of $7.46 million and total equity of -$5.76 million, resulting in a negative debt-to-equity ratio of -0.15. The company…

Dilution: Low · Liquidity: Medium
IHGP.PKOTC

Ihgp.Pk

Healthcare Facilities & Services
Kurs$0.00
Børsverdi
P/E
Omsetning$4,5 mill.
Driftsresultat-$2,1 mill.
FCF

IHGP.PK has a negative equity position of -$4.105 billion and a debt-to-equity ratio of -1.52, indicating a significant reliance on debt financing and a weak capital structure. The company's liquid…

Dilution: Low · Liquidity: Medium
INDISASantiago

Instituto de Diagnostico SA

Healthcare Facilities & Services
Kurs$2686.70
Børsverdi$412,22 mrd.
P/E26,4
Omsetning$272,31 mrd.
Driftsresultat$35,00 mrd.
FCF$18,52 mrd.

Instituto de Diagnostico SA maintains a market price of 2700.0, with a market capitalization of 414,261,718,200.0. The company's price-to-earnings ratio is 26.45, and its price-to-book ratio is 2.0…

Dilution: Low · Liquidity: Medium
INNO.CD

Inno.Cd

Pharmaceuticals
Kurs$5.00
Børsverdi
P/E
Omsetning$26,6 mill.
Driftsresultat-$1,3 mill.
FCF-$315,0k

INNO.CD has a current liquidity position characterized by a current ratio of 7.7, indicating strong short-term liquidity. However, the company reported negative net cash after subtracting total deb…

Dilution: Low · Liquidity: Medium
ISLBNSE (India)

Islb.Ns

Pharmaceuticals
Kurs$137.76
Børsverdi
P/E
Omsetning$5,62 mrd.
Driftsresultat$1,82 mrd.
FCF$2,11 mrd.

ISLB.NS maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating minimal leverage and a conservative approach to financing. The company's liquidity position is character…

Dilution: Low · Liquidity: Medium
JEEVBSE (India)

Jeev.Bo

Biotechnology & Medical Research
Kurs$83.91
Børsverdi
P/E
Omsetning$468,4 mill.
Driftsresultat$11,6 mill.
FCF-$97,2 mill.

JEEV.BO's capital structure is characterized by a debt-to-equity ratio of 0.41, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current…

Dilution: Low · Liquidity: Medium
KPRNNSE (India)

Kprn.Ns

Pharmaceuticals
Kurs$156.32
Børsverdi
P/E
Omsetning$6,30 mrd.
Driftsresultat$585,6 mill.
FCF-$192,4 mill.

KPRN.NS maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is assessed as medi…

Dilution: Low · Liquidity: Medium
KREBNSE (India)

Kreb.Ns

Pharmaceuticals
Kurs$56.10
Børsverdi
P/E
Omsetning$433,1 mill.
Driftsresultat-$217,2 mill.
FCF-$238,1 mill.

KREB.NS exhibits a highly leveraged capital structure, with total liabilities of INR 31.53 billion and total equity of INR -1.46 billion, resulting in a debt-to-equity ratio of -1.45. The company's…

Dilution: Low · Liquidity: Medium
KTMSMSET (Bangkok)

KT Medical Service Co Ltd

Healthcare Facilities & Services
Kurs
Børsverdi
P/E
Omsetning$456,1 mill.
Driftsresultat$21,3 mill.
FCF-$114,9 mill.

KTMSM.BK maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating limited leverage and a strong equity base. The company's liquidity position is mixed: while it ho…

Dilution: Low · Liquidity: Medium
LABSIDX (Jakarta)

PT UBC Medical Indonesia Tbk

Medical Equipment, Supplies & Distribution
Kurs$176.00
Børsverdi
P/E
Omsetning
Driftsresultat
FCF$3,24 mrd.

The company maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.31, indicating a conservative leverage position. However, its liquidity position is assessed as medium,…

Dilution: Low · Liquidity: Medium
LDDD.PKOTC

Lddd.Pk

Healthcare Providers & Services
Kurs$0.51
Børsverdi
P/E
Omsetning$4,3 mill.
Driftsresultat$552,7k
FCF$570,2k

LDDD.PK maintains a strong liquidity position, with a current ratio of 2.18, indicating the company can easily cover its short-term liabilities with its current assets. The company has no long-term…

Dilution: Low · Liquidity: Low
NOXASX

Noxopharm Ltd

Biotechnology & Medical Research
KursA$0.08
Børsverdi
P/E
Omsetning
Driftsresultat
FCF

Noxopharm Ltd has a basic and diluted share count of 307,237,950, indicating no immediate dilution pressure from share issuance. However, the company's liquidity position could not be assessed due…

Dilution: Low · Liquidity: Unknown
NSBASX

Neuroscientific Biopharmaceuticals Ltd

Biotechnology & Medical Research
KursA$0.07
BørsverdiA$23,6 mill.
P/E
OmsetningA$166,1k
Driftsresultat-A$1,8 mill.
FCF-A$1,8 mill.

NSB.AX maintains a strong liquidity position, with a current ratio of 49.56, indicating a significant excess of current assets over current liabilities. The company's price-to-book ratio of 1.98 su…

Dilution: Low · Liquidity: Low
PFSF.PKOTC

Pfsf.Pk

Biotechnology & Medical Research
Kurs$0.05
Børsverdi
P/E
Omsetning
Driftsresultat-$51,9k
FCF

PFSF.PK exhibits a negative equity position of -$162.46 million and no long-term debt, indicating a capital structure that is entirely equity-funded and currently in deficit. The company's liquidit…

Dilution: Low · Liquidity: Low
PHIL

Philadelphia Pharmaceuticals Industry Company PSC

Pharmaceuticals
Kurs$1.65
Børsverdi
P/E
Omsetning$2,3 mill.
Driftsresultat$335,2k
FCF-$244,2k

The company maintains a relatively strong liquidity position, with a current ratio of 2.57, indicating that it has more than twice as many current assets as current liabilities. However, its operat…

Dilution: Low · Liquidity: Medium
PYFAIDX (Jakarta)

Pyridam Farma Tbk PT

Pharmaceuticals
Kurs$242.00
Børsverdi$2,72 bill.
P/E
Omsetning$2,76 bill.
Driftsresultat-$217,20 mrd.
FCF-$256,15 mrd.

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 6.31, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a c…

Dilution: Low · Liquidity: Medium
RHTASX

Rht.Ax

Advanced Medical Equipment & Technology
KursA$0.04
Børsverdi
P/E
OmsetningA$11,2 mill.
Driftsresultat-A$1,8 mill.
FCF-A$1,4 mill.

ResMed operates with a debt-to-equity ratio of 0.4 and a current ratio of 1.28, indicating moderate liquidity and a balanced capital structure. However, the company has no cash and equivalents, and…

Dilution: Low · Liquidity: Medium
SALR.LJ

Salus Ljubljana dd

Pharmaceuticals
Kurs$62.50
Børsverdi
P/E
Omsetning$696,2 mill.
Driftsresultat$19,7 mill.
FCF$9,6 mill.

Salus Ljubljana dd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is chara…

Dilution: Low · Liquidity: Medium
SDPCIDX (Jakarta)

Sdpc.Jk

Pharmaceuticals
Kurs$190.00
Børsverdi$242,06 mrd.
P/E6,1
Omsetning$4,11 bill.
Driftsresultat$113,54 mrd.
FCF$10,23 mrd.

The company's capital structure is characterized by a high debt-to-equity ratio of 2.57, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a cu…

Dilution: Low · Liquidity: Medium
SPEABSE (India)

Spea.Bo

Pharmaceuticals
Kurs$269.85
Børsverdi
P/E
Omsetning$582,7 mill.
Driftsresultat$88,9 mill.
FCF$67,9 mill.

SPEA.BO maintains a strong liquidity position, as evidenced by a current ratio of 5.5, indicating that the company has sufficient current assets to cover its current liabilities multiple times over…

Dilution: Low · Liquidity: Medium
SUDABSE (India)

Suda.Bo

Pharmaceuticals
Kurs$30.02
Børsverdi
P/E
Omsetning$5,05 mrd.
Driftsresultat$348,8 mill.
FCF$184,7 mill.

SUDA.BO exhibits a debt-to-equity ratio of 1.3, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of…

Dilution: Low · Liquidity: Medium
SYFINSE (India)

Syncom Formulations (India) Ltd

Pharmaceuticals
Kurs$13.57
Børsverdi
P/E
Omsetning$745,7 mill.
Driftsresultat$81,3 mill.
FCF

Syncom Formulations maintains a relatively strong liquidity position, with a current ratio of 2.59, indicating that it has more than twice the current assets to cover its current liabilities. Howev…

Dilution: Low · Liquidity: Medium
TNPH.PKOTC

Tnph.Pk

Pharmaceuticals
Kurs$0.01
Børsverdi
P/E
Omsetning$10,7 mill.
Driftsresultat$3,7 mill.
FCF

TNPH.PK maintains a strong liquidity position, with a current ratio of 14.21, indicating a significant ability to cover short-term liabilities with its current assets. The company holds $8.226 mill…

Dilution: Low · Liquidity: Low
TNZTPBorsa Istanbul

Tapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS

Healthcare Facilities & Services
Kurs$25.60
Børsverdi
P/E
Omsetning$3,43 mrd.
Driftsresultat$972,7 mill.
FCF$614,9 mill.

The company maintains a strong capital structure with a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing. However, its liquidity position is rated as medium, with negative…

Dilution: Low · Liquidity: Medium
TOITSX Venture

Topicus.com Inc

Healthcare Providers & Services
KursC$101.99
BørsverdiC$8,52 mrd.
P/E184,2
OmsetningC$1,55 mrd.
DriftsresultatC$233,2 mill.
FCFC$263,7 mill.

Topicus.com Inc maintains a capital structure characterized by significant leverage, with a debt-to-equity ratio of 1.67 and total liabilities of €2.04 billion against total equity of €474 million.…

Dilution: Low · Liquidity: Medium
TXMDNASDAQ

TherapeuticsMD Inc

Diversified Pharmaceuticals
Kurs$2.04
Børsverdi$23,6 mill.
P/E
Omsetning$3,0 mill.
Driftsresultat-$4,4 mill.
FCF-$269,0k

TherapeuticsMD Inc has a market capitalization of $23.6 million and a price-to-book ratio of 0.88, indicating that the company is trading at a discount to its book value. The company has no long-te…

Dilution: Low · Liquidity: Low
VVTMTSX Venture

Vvtm.V

Medical Equipment, Supplies & Distribution
KursC$0.30
Børsverdi
P/E
Omsetning
Driftsresultat-C$115,3k
FCF-C$115,3k

The company's capital structure is highly leveraged, with total liabilities of $794,158 million and total equity of -$775,382 million, resulting in a negative debt-to-equity ratio of -0.72. Liquidi…

Dilution: Low · Liquidity: Medium
WATASX

Waterco Ltd

Advanced Medical Equipment & Technology
KursA$5.13
Børsverdi
P/E
Omsetning
Driftsresultat
FCF

Waterco's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in source documents. The comp…

Dilution: Low · Liquidity: Unknown
ZJYLNASDAQ

Jin Medical International Ltd

Diversified Medical Equipment & Supplies
Kurs$1.93
Børsverdi
P/E
Omsetning$20,7 mill.
Driftsresultat$608,2k
FCF-$5,0 mill.

Jin Medical International Ltd maintains a debt-to-equity ratio of 0.64, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current rati…

Dilution: Low · Liquidity: Medium
000705Shenzhen Stock Exchange

Zhejiang Zhenyuan Share Co Ltd

Pharmaceuticals
Kurs$7.64
Børsverdi
P/E
Omsetning$914,2 mill.
Driftsresultat$26,7 mill.
FCF

Zhejiang Zhenyuan maintains a conservative capital structure with a debt-to-equity ratio of 0.11, indicating a low reliance on debt financing. The company's liquidity position is characterized as m…

Dilution: Low · Liquidity: Medium
0010V0KOSDAQ

JPI Healthcare Co Ltd

Advanced Medical Equipment & Technology
Kurs$8185.00
Børsverdi$41,79 mrd.
P/E36,1
Omsetning$10,99 mrd.
Driftsresultat$960,5 mill.
FCF$1,49 mrd.

JPI Healthcare Co Ltd has a market capitalization of KRW 4,977,765,000,000 and a price-to-earnings ratio of 36.12, indicating a relatively high valuation compared to its earnings. The company repor…

Dilution: Low · Liquidity: Unknown
002688Shenzhen Stock Exchange

Jinhe Biotechnology Co Ltd

Pharmaceuticals
Kurs$5.88
Børsverdi
P/E
Omsetning$546,3 mill.
Driftsresultat$51,0 mill.
FCF

Jinhe Biotechnology maintains a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. The company's current ratio of 1.07 suggests it has just enough current assets to cov…

Dilution: Low · Liquidity: Medium
0455HKEX

0455.Hk

Pharmaceuticals
KursHK$0.09
BørsverdiHK$195,7 mill.
P/E
OmsetningHK$322,9 mill.
Driftsresultat-HK$65,8 mill.
FCF

The company's capital structure is characterized by a debt-to-equity ratio of 0.29, indicating a relatively conservative leverage position. However, the company is currently operating with a negati…

Dilution: Low · Liquidity: Medium
063160KRX

CKD Bio Corp

Pharmaceuticals
Kurs₩13690.00
Børsverdi₩75,10 mrd.
P/E34,7
Omsetning₩45,54 mrd.
Driftsresultat₩3,19 mrd.
FCF₩5,17 mrd.

CKD Bio Corp has a market price of 17,930 KRW and a market capitalization of 98,363,244,870 KRW, with a price-to-earnings ratio of 34.74 and a price-to-book ratio of 0.78. The company's liquidity p…

Dilution: Low · Liquidity: Medium
065660KOSDAQ

Anterogen Co Ltd

Pharmaceuticals
Kurs$30400.00
Børsverdi
P/E
Omsetning$7,54 mrd.
Driftsresultat-$2,43 mrd.
FCF-$1,05 mrd.

Anterogen maintains a strong liquidity position with a current ratio of 78.12, indicating that its current assets significantly exceed its current liabilities. The company holds KRW 1.58 billion in…

Dilution: Low · Liquidity: Low
1813TPEx

1813.Two

Medical Equipment, Supplies & Distribution
Kurs$12.20
Børsverdi$568,9 mill.
P/E
Omsetning$304,3 mill.
Driftsresultat-$127,3 mill.
FCF-$13,3 mill.

The company's capital structure is characterized by a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position. Its liquidity position is marked by a current ratio of 1.…

Dilution: Low · Liquidity: Medium
188260KOSDAQ

188260.Kq

Medical Equipment, Supplies & Distribution
Kurs$1589.00
Børsverdi
P/E
Omsetning$15,35 mrd.
Driftsresultat-$4,37 mrd.
FCF-$5,09 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 1.05, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…

Dilution: Low · Liquidity: Medium
194ATokyo Stock Exchange

194a.T

Healthcare Facilities & Services
Kurs¥1235.00
Børsverdi
P/E
Omsetning¥5,46 mrd.
Driftsresultat¥900,0 mill.
FCF¥827,2 mill.

194A.T maintains a capital structure with a debt-to-equity ratio of 0.93, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a curre…

Dilution: Low · Liquidity: Medium
196300KOSDAQ

HLB Pep Co Ltd

Biotechnology & Medical Research
Kurs$4705.00
Børsverdi
P/E
Omsetning$2,51 mrd.
Driftsresultat-$1,12 mrd.
FCF-$783,7 mill.

HLB Pep Co Ltd exhibits a capital structure with a debt-to-equity ratio of 0.78, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a cur…

Dilution: Low · Liquidity: Medium
241820KOSDAQ

PCL Inc

Biotechnology & Medical Research
Kurs
Børsverdi
P/E
Omsetning$6,70 mrd.
Driftsresultat-$3,15 mrd.
FCF-$3,12 mrd.

PCL Inc's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate reliance on debt financing. The company holds cash and equivalents of KRW 6,397.8 billion, but…

Dilution: Low · Liquidity: Medium
246720KOSDAQ

246720.Kq

Medical Equipment, Supplies & Distribution
Kurs$6070.00
Børsverdi
P/E
Omsetning$2,59 mrd.
Driftsresultat-$2,59 mrd.
FCF-$2,78 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 0.3, indicating a relatively conservative leverage position. Despite holding significant cash and equivalents of KRW 2,…

Dilution: Low · Liquidity: Low
300238Shenzhen Stock Exchange

Guanhao Biotech Co Ltd

Medical Equipment, Supplies & Distribution
Kurs$12.30
Børsverdi
P/E
Omsetning$387,7 mill.
Driftsresultat$30,4 mill.
FCF-$1,8 mill.

Guanhao Biotech maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.22, indicating a low reliance on debt financing. The company's liquidity position is characte…

Dilution: Low · Liquidity: Medium
300396Shenzhen Stock Exchange

Dirui Industrial Co Ltd

Medical Equipment, Supplies & Distribution
Kurs$7.70
Børsverdi
P/E
Omsetning$807,1 mill.
Driftsresultat
FCF

Dirui Industrial Co Ltd maintains a debt-to-equity ratio of 0.29, indicating a relatively conservative capital structure with equity financing playing a dominant role in its capital base. The compa…

Dilution: Low · Liquidity: Medium
300519Shenzhen Stock Exchange

Zhejiang Xinguang Pharmaceutical Co Ltd

Pharmaceuticals
Kurs$15.80
Børsverdi$2,53 mrd.
P/E868,9
Omsetning$45,7 mill.
Driftsresultat$2,4 mill.
FCF

Zhejiang Xinguang Pharmaceutical Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 11.02, indicating that the company has significantly more current assets than curre…

Dilution: Low · Liquidity: Medium
300705Shenzhen Stock Exchange

Hunan Jiudian Pharmaceutical Co Ltd

Pharmaceuticals
Kurs$11.77
Børsverdi$5,89 mrd.
P/E12,4
Omsetning$3,11 mrd.
Driftsresultat$533,5 mill.
FCF-$218,7 mill.

Hunan Jiudian Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 3.64, indicating that it has sufficient current assets to cover its current liabilities…

Dilution: Low · Liquidity: Medium
311ATokyo Stock Exchange

311a.T

Biotechnology & Medical Research
Kurs¥0.00
Børsverdi
P/E
Omsetning
Driftsresultat-¥215,5 mill.
FCF

311A.T has a strong liquidity position, as evidenced by a current ratio of 7.1, indicating that the company holds significantly more current assets than current liabilities. The company maintains a…

Dilution: Low · Liquidity: Low
314140KOSDAQ

RP Bio lnc

Pharmaceuticals
Kurs$5450.00
Børsverdi
P/E
Omsetning$32,49 mrd.
Driftsresultat-$262,0 mill.
FCF$630,0 mill.

RP Bio lnc's capital structure is characterized by a debt-to-equity ratio of 0.3, indicating a relatively conservative leverage position compared to the industry median of 0.8. The company maintain…

Dilution: Low · Liquidity: Medium
317690KOSDAQ

317690.Kq

Medical Equipment, Supplies & Distribution
Kurs$2800.00
Børsverdi
P/E
Omsetning$3,69 mrd.
Driftsresultat-$16,52 mrd.
FCF-$17,96 mrd.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.24, indicating a conservative leverage profile. It holds a substantial amount of cash and equivalents, amounting…

Dilution: Low · Liquidity: Low
321550KOSDAQ

TiumBio Co Ltd

Biotechnology & Medical Research
Kurs$7560.00
Børsverdi$219,33 mrd.
P/E
Omsetning$12,29 mrd.
Driftsresultat-$17,27 mrd.
FCF-$15,63 mrd.

TiumBio operates with a capital structure that shows a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current…

Dilution: Low · Liquidity: Medium
338840KOSDAQ

Y Biologics Inc

Biotechnology & Medical Research
Kurs$17550.00
Børsverdi
P/E
Omsetning$2,91 mrd.
Driftsresultat-$9,83 mrd.
FCF-$41,55 mrd.

Y Biologics Inc maintains a strong liquidity position with cash and equivalents amounting to KRW 38,922,143,940, which significantly exceeds its total liabilities of KRW 29,200,450,880. The company…

Dilution: Low · Liquidity: Low
348080KOSDAQ

Quratis Inc

Pharmaceuticals
Kurs$444.00
Børsverdi
P/E
Omsetning$68,5 mill.
Driftsresultat-$4,16 mrd.
FCF-$3,73 mrd.

Quratis Inc has a capital structure characterized by a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a…

Dilution: Low · Liquidity: Medium
354390.KN

354390.Kn

Pharmaceuticals
Kurs$4325.00
Børsverdi
P/E
Omsetning$33,52 mrd.
Driftsresultat$2,89 mrd.
FCF$5,94 mrd.

The company maintains a strong liquidity position, with a current ratio of 6.87, indicating a significant buffer of current assets over current liabilities. It also holds substantial cash and equiv…

Dilution: Low · Liquidity: Low
359090KOSDAQ

359090.Kq

Biotechnology & Medical Research
Kurs$550.00
Børsverdi$31,61 mrd.
P/E14,1
Omsetning$64,98 mrd.
Driftsresultat$1,38 mrd.
FCF$1,29 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 8,848,468,100, which represents 10.45% of total assets. The liquidity FPT (free cash flow to total liab…

Dilution: Low · Liquidity: Low
372910KRX

Hancom Lifecare Inc

Medical Equipment, Supplies & Distribution
Kurs₩1759.00
Børsverdi
P/E
Omsetning₩13,64 mrd.
Driftsresultat-₩847,0 mill.
FCF₩467,6 mill.

Hancom Lifecare Inc has a strong liquidity position, with cash and equivalents amounting to KRW 10,510,215,160, which is significantly higher than its short-term liabilities. The company's liquidit…

Dilution: Low · Liquidity: Low
389030KOSDAQ

389030.Kq

Biotechnology & Medical Research
Kurs$4175.00
Børsverdi$139,24 mrd.
P/E
Omsetning$10,48 mrd.
Driftsresultat-$11,67 mrd.
FCF-$15,51 mrd.

The company has a high price-to-book ratio of 14.64, indicating that the market values the company significantly above its book value. The price-to-tangible-book ratio is also 14.64, suggesting tha…

Dilution: Low · Liquidity: Medium
4178TPEx

StemCyte International Ltd

Biotechnology & Medical Research
Kurs
Børsverdi
P/E
Omsetning$382,7 mill.
Driftsresultat-$259,8 mill.
FCF-$173,8 mill.

StemCyte's capital structure is characterized by a relatively low debt-to-equity ratio of 0.13, indicating a conservative leverage profile. The company holds TWD 98.4 million in cash and equivalent…

Dilution: Low · Liquidity: Medium
419540KOSDAQ

419540.Kq

Advanced Medical Equipment & Technology
Kurs$2970.00
Børsverdi
P/E
Omsetning$17,10 mrd.
Driftsresultat-$1,10 mrd.
FCF-$427,3 mill.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage position. However, the company has negative operating and free cash flows,…

Dilution: Low · Liquidity: Medium
4556Tokyo Stock Exchange

4556.T

Medical Equipment, Supplies & Distribution
Kurs¥2268.00
Børsverdi¥9,56 mrd.
P/E14,9
Omsetning¥5,31 mrd.
Driftsresultat¥822,4 mill.
FCF¥525,0 mill.

The company maintains a strong liquidity position, with a current ratio of 4.0, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to ¥3,396,322,000, which…

Dilution: Low · Liquidity: Low
456070KOSDAQ

456070.Kq

Biotechnology & Medical Research
Kurs$13220.00
Børsverdi$144,35 mrd.
P/E
Omsetning$5,26 mrd.
Driftsresultat-$17,89 mrd.
FCF-$14,55 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 13,999,999,610, which is significantly higher than its total liabilities of KRW 24,309,226,940. The cur…

Dilution: Low · Liquidity: Low
4575Tokyo Stock Exchange

4575.T

Pharmaceuticals
Kurs¥568.00
Børsverdi¥11,19 mrd.
P/E
Omsetning
Driftsresultat-¥1,11 mrd.
FCF

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2.83 billion, representing 92.7% of total assets. The liquidity FPT (free cash flow to total assets) is no…

Dilution: Low · Liquidity: Low
461030KOSDAQ

461030.Kq

Biotechnology & Medical Research
Kurs$4445.00
Børsverdi$62,31 mrd.
P/E
Omsetning$5,33 mrd.
Driftsresultat-$8,66 mrd.
FCF-$7,51 mrd.

The company maintains a strong liquidity position, with a current ratio of 15.37, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to KRW…

Dilution: Low · Liquidity: Low
464490KOSDAQ

464490.Kq

Biotechnology & Medical Research
Kurs$10890.00
Børsverdi
P/E
Omsetning$10,70 mrd.
Driftsresultat-$6,38 mrd.
FCF-$6,05 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 26.5 billion, representing a significant portion of its total assets of KRW 51.2 billion. The liquidity…

Dilution: Low · Liquidity: Low
600807Shanghai Stock Exchange

600807.Ss

Medical Equipment, Supplies & Distribution
Kurs$2.97
Børsverdi$2,63 mrd.
P/E
Omsetning$372,2 mill.
Driftsresultat-$175,9 mill.
FCF-$879,6 mill.

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 13.62, indicating a significant reliance on debt financing. Despite a current ratio of 1.36, suggesting moderate…

Dilution: Low · Liquidity: Medium
6499TPEx

Medeon Biodesign Inc

Advanced Medical Equipment & Technology
Kurs$86.30
Børsverdi$8,37 mrd.
P/E
Omsetning$419,4 mill.
Driftsresultat-$722,5 mill.
FCF-$628,9 mill.

Medeon Biodesign Inc has a market capitalization of approximately TWD 8.6 billion and a price-to-book ratio of 5.83, indicating a premium valuation relative to its book value. The company's liquidi…

Dilution: Low · Liquidity: Medium
6586TPEx

6586.Two

Pharmaceuticals
Kurs$64.90
Børsverdi
P/E
Omsetning$1,4 mill.
Driftsresultat-$325,8 mill.
FCF-$275,0 mill.

The company exhibits a highly liquid capital structure, with a current ratio of 19.47, indicating a strong ability to meet short-term obligations. Despite this, the company reported negative operat…

Dilution: Low · Liquidity: Low
6659TPEx

6659.Two

Pharmaceuticals
Kurs$20.75
Børsverdi
P/E
Omsetning$1,36 mrd.
Driftsresultat$53,2 mill.
FCF$68,0 mill.

6659.TWO has a debt-to-equity ratio of 0.79, indicating a moderate level of leverage, and a current ratio of 1.15, suggesting limited short-term liquidity cushion. The company reported negative net…

Dilution: Low · Liquidity: Medium
6794TWSE

Unicocell Biomed Co Ltd

Biotechnology & Medical Research
Kurs$79.00
Børsverdi
P/E
Omsetning$30,1 mill.
Driftsresultat-$130,3 mill.
FCF-$100,0 mill.

Unicocell Biomed Co Ltd maintains a strong liquidity position with a current ratio of 37.98, indicating that its current assets significantly exceed its current liabilities. However, the company ha…

Dilution: Low · Liquidity: Medium
6827TPEx

6827.Two

Biotechnology & Medical Research
Kurs$11.60
Børsverdi
P/E
Omsetning$0,00
Driftsresultat-$119,6 mill.
FCF-$104,9 mill.

6827.TWO maintains a strong liquidity position, with a current ratio of 16.17, indicating a high ability to meet short-term obligations. The company holds cash and equivalents of TWD 112.28 million…

Dilution: Low · Liquidity: Low
7881TPEx

7881.Two

Medical Equipment, Supplies & Distribution
Kurs$99.70
Børsverdi
P/E
Omsetning$656,5 mill.
Driftsresultat$66,3 mill.
FCF$54,9 mill.

The company's capital structure is characterized by a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…

Dilution: Low · Liquidity: Medium
ACUASX

Acu.Ax

Diversified Medical Equipment & Supplies
KursA$0.08
Børsverdi
P/E
OmsetningA$58,3 mill.
DriftsresultatA$1,9 mill.
FCFA$2,3 mill.

ACU.AX maintains a conservative capital structure with a low debt-to-equity ratio of 0.08, indicating minimal reliance on debt financing. The company's liquidity position is characterized as medium…

Dilution: Low · Liquidity: Medium
ADCI

Arab Drug Company for Pharmaceuticals and Chemical Industries SAE

Pharmaceuticals
Kurs$218.60
Børsverdi
P/E
Omsetning$167,2 mill.
Driftsresultat$10,4 mill.
FCF-$14,0 mill.

Arab Drug Company for Pharmaceuticals and Chemical Industries SAE maintains a debt-to-equity ratio of 1.19, indicating a moderate level of leverage. The company's liquidity is assessed as medium, w…

Dilution: Low · Liquidity: Medium
ADOASX

Ado.Ax

Biotechnology & Medical Research
KursA$0.03
Børsverdi
P/E
OmsetningA$1,0 mill.
Driftsresultat-A$9,2 mill.
FCF-A$5,9 mill.

The company's capital structure is characterized by a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing. Liquidity is assessed as medium, with a current ratio of 2.08,…

Dilution: Low · Liquidity: Medium
AKBANASDAQ

Akebia Therapeutics Inc

Pharmaceuticals
Kurs$1.34
Børsverdi$359,5 mill.
P/E
Omsetning$236,2 mill.
Driftsresultat$23,5 mill.
FCF-$12,2 mill.

Akebia Therapeutics Inc (AKBA.O) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the lat…

Dilution: Low · Liquidity: Medium
AMRNNSE (India)

ADF Foods Ltd

Pharmaceuticals & Medical Research
Kurs$270.30
Børsverdi
P/E
Omsetning$5,90 mrd.
Driftsresultat$801,1 mill.
FCF$264,8 mill.

ADF Foods Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating a strong equity position relative to liabilities. The company's liquidity is assessed as med…

Dilution: Low · Liquidity: Medium
ASIVSGX

Asiv.Si

Healthcare Facilities & Services
Kurs$0.09
Børsverdi
P/E
Omsetning$2,3 mill.
Driftsresultat-$6,5 mill.
FCF-$6,1 mill.

ASIV.SI exhibits a strong liquidity position, with a current ratio of 13.32, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equ…

Dilution: Low · Liquidity: Low
AT1ASX

At1.Ax

Advanced Medical Equipment & Technology
KursA$0.02
Børsverdi
P/E
OmsetningA$3,8 mill.
Driftsresultat-A$5,0 mill.
FCF-A$3,4 mill.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative approach to leverage. However, the company's liquidity position is assessed as medi…

Dilution: Low · Liquidity: Medium
BIBB.TE

BibbInstruments AB

Advanced Medical Equipment & Technology
Kurs$0.50
Børsverdi
P/E
Omsetning$0,00
Driftsresultat-$3,0 mill.
FCF-$4,4 mill.

BibbInstruments AB has a current liquidity position characterized by a current ratio of 2.03, indicating that the company holds twice as many current assets as current liabilities. However, the com…

Dilution: Low · Liquidity: Low
BIOC

GlaxoSmithKline SAE

Pharmaceuticals
Kurs$76.52
Børsverdi$6,39 mrd.
P/E
Omsetning$713,8 mill.
Driftsresultat$69,4 mill.
FCF-$30,0 mill.

The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.08, indicating a conservative leverage position. However, the negative operating cash flow of -187,089…

Dilution: Low · Liquidity: Medium
BMPG.SG

B.M.P. Pharma Trading AG

Pharmaceuticals
Kurs$6.25
Børsverdi
P/E
Omsetning$1,6k
Driftsresultat-$2,0 mill.
FCF

BMPG.SG exhibits a strong liquidity position, with a current ratio of 53.44, indicating that the company holds significantly more current assets than current liabilities. However, the company's net…

Dilution: Low · Liquidity: Medium
BNXT.CD

BioNxt Solutions Inc

Pharmaceuticals
Kurs$0.43
Børsverdi
P/E
Omsetning$4,1k
Driftsresultat-$1,4 mill.
FCF-$1,6 mill.

BioNxt Solutions Inc exhibits a highly leveraged capital structure, with total liabilities of CAD 6.92 million and total equity of CAD -6.13 million, resulting in a negative debt-to-equity ratio of…

Dilution: Low · Liquidity: Medium
CHL.CM

Chl.Cm

Healthcare Facilities & Services
Kurs$63.50
Børsverdi
P/E
Omsetning$9,75 mrd.
Driftsresultat$1,16 mrd.
FCF$764,7 mill.

CHL.CM maintains a conservative capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as m…

Dilution: Low · Liquidity: Medium
CORLBSE (India)

Coral Laboratories Ltd

Pharmaceuticals
Kurs$455.20
Børsverdi
P/E
Omsetning$288,9 mill.
Driftsresultat$56,5 mill.
FCF

Coral Laboratories Ltd maintains a strong liquidity position, as evidenced by a current ratio of 6.18, indicating that the company has significantly more current assets than current liabilities. Th…

Dilution: Low · Liquidity: Low
DSHMNSE (India)

Dshm.Ns

Pharmaceuticals
Kurs$194.25
Børsverdi
P/E
Omsetning$27,11 mrd.
Driftsresultat$1,68 mrd.
FCF$802,1 mill.

DSHM.NS has a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium…

Dilution: Low · Liquidity: Medium
GWAY.CD

Gway.Cd

Healthcare Facilities & Services
Kurs$0.18
Børsverdi
P/E
Omsetning$8,9 mill.
Driftsresultat-$958,9k
FCF-$320,4k

GWAY.CD's capital structure is characterized by a debt-to-equity ratio of 1.57, indicating a relatively high level of leverage. The company's liquidity position is assessed as medium, with a curren…

Dilution: Low · Liquidity: Medium
HEMOLondon Stock Exchange

Hemogenyx Pharmaceuticals PLC

Biotechnology & Medical Research
Kurs$775.00
Børsverdi$4,98 mrd.
P/E
Omsetning
Driftsresultat
FCF

HEMO.L's capital structure is characterized by a debt-to-equity ratio of 1.68, indicating a relatively high level of leverage. The company holds $1.59 billion in cash and equivalents, but this is o…

Dilution: Low · Liquidity: Medium
HEXRBursa Malaysia

Hexr.Kl

Medical Equipment, Supplies & Distribution
Kurs$0.42
Børsverdi
P/E
Omsetning$148,1 mill.
Driftsresultat-$35,5 mill.
FCF-$36,2 mill.

HEXR.KL's capital structure is characterized by a very low debt-to-equity ratio of 0.01, indicating a conservative leverage profile. The company's liquidity position is moderate, with a current rat…

Dilution: Low · Liquidity: Medium
ISRGTASE (Tel Aviv)

Isrg.Ta

Advanced Medical Equipment & Technology
Kurs$151.20
Børsverdi$39,68 mrd.
P/E2858,3
Omsetning$690,0 mill.
Driftsresultat$25,9 mill.
FCF-$17,7 mill.

ISRG.TA has a high price-to-book ratio of 353.36, indicating that the market values the company significantly above its book value. The company's liquidity position is weak, as evidenced by a curre…

Dilution: Low · Liquidity: Medium
JANL.PKOTC

Janel Group LLC

Diversified Pharmaceuticals
Kurs$58.00
Børsverdi
P/E
Omsetning$207,4 mill.
Driftsresultat$6,4 mill.
FCF$7,0 mill.

JANL.PK has a liquidity position that is below the industry median, with a current ratio of 0.74, indicating that the company's current assets are less than its current liabilities. The company's c…

Dilution: Low · Liquidity: Medium
JGSNNSE (India)

Jagsonpal Pharmaceuticals Ltd

Pharmaceuticals
Kurs$212.29
Børsverdi
P/E
Omsetning$614,4 mill.
Driftsresultat$58,8 mill.
FCF

Jagsonpal Pharmaceuticals Ltd operates with a capital structure that includes a basic and diluted share count of 67.14 million shares, with no dilution observed in the latest reporting period. The…

Dilution: Low · Liquidity: Unknown
JTH0.MU

Jth0.Mu

Healthcare Facilities & Services
Kurs$11.50
Børsverdi
P/E
Omsetning$78,2 mill.
Driftsresultat$3,9 mill.
FCF-$2,9 mill.

JTH0.MU has a liquidity position that is moderate, with a current ratio of 2.81, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's free…

Dilution: Low · Liquidity: Medium
MDNC.PKOTC

Mdnc.Pk

Diversified Medical Equipment & Supplies
Kurs$5.00
Børsverdi
P/E
Omsetning$9,1 mill.
Driftsresultat$3,2 mill.
FCF$2,2 mill.

MDNC.PK maintains a strong liquidity position with a current ratio of 4.27, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity_fpt score…

Dilution: Low · Liquidity: Medium
MIPH

Miph.Ca

Pharmaceuticals
Kurs$685.30
Børsverdi
P/E
Omsetning$5,66 mrd.
Driftsresultat$693,2 mill.
FCF-$513,4 mill.

MIPH.CA maintains a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing, and a current ratio of 1.25, suggesting it has sufficient short-term assets to cover its short-te…

Dilution: Low · Liquidity: Medium
NACPNSE (India)

Nacp.Ns

Pharmaceuticals
Kurs$152.20
Børsverdi
P/E
Omsetning$1,69 mrd.
Driftsresultat$82,8 mill.
FCF-$348,9 mill.

NACP.NS exhibits a capital structure with a debt-to-equity ratio of 0.45, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio…

Dilution: Low · Liquidity: Medium
NDC

Ndc.Hno

Pharmaceuticals
Kurs$157000.00
Børsverdi
P/E
Omsetning$928,00 mrd.
Driftsresultat$113,67 mrd.
FCF$56,82 mrd.

NDC.HNO maintains a strong liquidity position, with a current ratio of 2.56, indicating that the company has more than double the current assets to cover its current liabilities. The company also h…

Dilution: Low · Liquidity: Low
PETV.PKOTC

PetVivo Holdings Inc

Diversified Medical Equipment & Supplies
Kurs$0.64
Børsverdi
P/E
Omsetning$48,3k
Driftsresultat-$2,6 mill.
FCF-$2,6 mill.

PetVivo operates with a liquidity position that is below the industry median, as evidenced by a current ratio of 0.74, indicating that the company's current liabilities exceed its current assets. T…

Dilution: Low · Liquidity: Medium
PHAR.CM

Colombo City Holdings PLC

Pharmaceuticals
Kurs$158.25
Børsverdi
P/E
Omsetning$50,0 mill.
Driftsresultat$195,6 mill.
FCF$258,0 mill.

Colombo City Holdings PLC maintains a strong liquidity position, with a current ratio of 4.75, indicating the company can cover its short-term liabilities more than four times over. However, the co…

Dilution: Low · Liquidity: Medium
PHGSET (Bangkok)

Phg.Bk

Health Care
Kurs$11.90
Børsverdi
P/E
Omsetning$2,51 mrd.
Driftsresultat$388,0 mill.
FCF$195,7 mill.

The company maintains a strong liquidity position, with a current ratio of 4.93, indicating a robust ability to meet short-term obligations. The liquidity_fpt metric further supports this, showing…

Dilution: Low · Liquidity: Low
PLRZNASDAQ

Polyrizon Ltd

Biotechnology & Medical Research
Kurs$10.59
Børsverdi$18,9 mill.
P/E
Omsetning
Driftsresultat-$6,2 mill.
FCF-$3,0 mill.

Polyrizon maintains a strong liquidity position, with a current ratio of 29.03, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount…

Dilution: Low · Liquidity: Low
QMSMNSE (India)

QMS Medical Allied Services Ltd

Medical Equipment, Supplies & Distribution
Kurs$95.30
Børsverdi
P/E
Omsetning$322,9 mill.
Driftsresultat$30,6 mill.
FCF

QMS Medical Allied Services Ltd maintains a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity…

Dilution: Low · Liquidity: Medium
QUETNSE (India)

Quet.Ns

Pharmaceuticals
Kurs$117.25
Børsverdi
P/E
Omsetning$1,04 mrd.
Driftsresultat$153,5 mill.
FCF$107,3 mill.

Quetell's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to the industry median of 0.52. The company's liquidi…

Dilution: Low · Liquidity: Medium
RVXTSX

Rvx.To

Biotechnology & Medical Research
KursC$0.10
Børsverdi
P/E
Omsetning
Driftsresultat-C$5,1 mill.
FCF-C$8,0 mill.

RVX.TO's capital structure is characterized by a significant debt burden, with total liabilities of $96.91 million and total equity of -$88.96 million, resulting in a debt-to-equity ratio of -0.69.…

Dilution: Low · Liquidity: Medium
SANCBursa Malaysia

Sanc.Kl

Advanced Medical Equipment & Technology
Kurs$0.00
Børsverdi
P/E
Omsetning$3,5 mill.
Driftsresultat$2,2 mill.
FCF-$469,5k

SANC.KL maintains a strong liquidity position with a current ratio of 10.18, indicating a high ability to meet short-term obligations. However, the company reported negative net cash of MYR -391,67…

Dilution: Low · Liquidity: Medium
SBMHTSX Venture

Sirona Biochem Corp

Biotechnology & Medical Research
Kurs
Børsverdi
P/E
OmsetningC$18,1k
Driftsresultat-C$363,5k
FCF-C$361,7k

Sirona Biochem Corp has a liquidity position that is currently medium, with a current ratio of 1.47, indicating that the company has sufficient short-term assets to cover its short-term liabilities…

Dilution: Low · Liquidity: Medium
TOGSET (Bangkok)

Thai Optical Group PCL

Medical Equipment, Supplies & Distribution
Kurs$6.65
Børsverdi
P/E
Omsetning$844,5 mill.
Driftsresultat$133,1 mill.
FCF$142,5 mill.

Thai Optical Group PCL maintains a debt-to-equity ratio of 0.55, indicating a moderate level of leverage relative to its equity base. The company's liquidity position is characterized by a current…

Dilution: Low · Liquidity: Medium
TRIASX

Tri.Ax

Pharmaceuticals
KursA$0.02
Børsverdi
P/E
OmsetningA$1,1 mill.
Driftsresultat-A$909,6k
FCF-A$3,0 mill.

TRI.AX has a liquidity position that is characterized by a current ratio of 1.86, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's…

Dilution: Low · Liquidity: Medium
UNLBNSE (India)

Unichem Laboratories Ltd

Pharmaceuticals
Kurs$349.35
Børsverdi
P/E
Omsetning$21,11 mrd.
Driftsresultat$1,40 mrd.
FCF$1,24 mrd.

Unichem Laboratories Ltd maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.19, indicating a low reliance on debt financing. The company's liquidity position is asses…

Dilution: Low · Liquidity: Medium
VIHSET (Bangkok)

Srivichai vejvivat PCL

Healthcare Facilities & Services
Kurs$8.85
Børsverdi
P/E
Omsetning$3,06 mrd.
Driftsresultat$547,7 mill.
FCF$277,9 mill.

Srivichai Vejvivat PCL maintains a strong capital structure with a low debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. The company's liquidity position is characterized…

Dilution: Low · Liquidity: Medium
YSPSBursa Malaysia

Ysps.Kl

Pharmaceuticals
Kurs$2.09
Børsverdi
P/E
Omsetning$365,1 mill.
Driftsresultat$38,2 mill.
FCF$17,4 mill.

YSPS.KL maintains a strong liquidity position, with a current ratio of 5.27, indicating the company can easily cover its short-term liabilities with its current assets. The company's cash and equiv…

Dilution: Low · Liquidity: Low
000230KRX

Ildong Holdings Co Ltd

Pharmaceuticals
Kurs₩6350.00
Børsverdi₩73,28 mrd.
P/E
Omsetning₩161,86 mrd.
Driftsresultat-₩3,82 mrd.
FCF-₩3,27 mrd.

Ildong Holdings exhibits a highly leveraged capital structure, with total liabilities of KRW 823.97 billion and total equity of KRW 30.96 billion, resulting in a debt-to-equity ratio of 12.23. The…

Dilution: Low · Liquidity: Medium
000590Shenzhen Stock Exchange

Guhan Pharmaceutical Group Co Ltd

Pharmaceuticals
Kurs$10.46
Børsverdi
P/E
Omsetning$69,6 mill.
Driftsresultat-$13,0 mill.
FCF

Guhan Pharmaceutical Group Co Ltd has a debt-to-equity ratio of 0.22, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is assessed as m…

Dilution: Low · Liquidity: Medium
003520KRX

Yungjin Pharm Co Ltd

Pharmaceuticals
Kurs₩1219.00
Børsverdi
P/E
Omsetning₩64,95 mrd.
Driftsresultat₩4,32 mrd.
FCF₩3,08 mrd.

Yungjin Pharm maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current r…

Dilution: Low · Liquidity: Medium
006140KOSDAQ

006140.Kq

Advanced Medical Equipment & Technology
Kurs$5060.00
Børsverdi$75,22 mrd.
P/E10,2
Omsetning$178,55 mrd.
Driftsresultat$10,96 mrd.
FCF$5,48 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 24,000,425,590, which is 41.3% of total assets. The liquidity FPT (free cash flow to total liabilities)…

Dilution: Low · Liquidity: Medium
014570KOSDAQ

014570.Kq

Pharmaceuticals
Kurs$3405.00
Børsverdi$36,84 mrd.
P/E6,0
Omsetning$62,51 mrd.
Driftsresultat$6,91 mrd.
FCF$6,27 mrd.

The company maintains a strong liquidity position, with a current ratio of 8.33, indicating a high ability to meet short-term obligations. Its cash and equivalents amount to KRW 4,847,182,630, and…

Dilution: Low · Liquidity: Low
018620KOSDAQ

018620.Kq

Pharmaceuticals
Kurs$2527.00
Børsverdi
P/E
Omsetning$54,76 mrd.
Driftsresultat$1,50 mrd.
FCF-$2,19 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is a…

Dilution: Low · Liquidity: Medium
038070KOSDAQ

Seoulin Bioscience Co Ltd

Biotechnology & Medical Research
Kurs$5030.00
Børsverdi
P/E
Omsetning$18,87 mrd.
Driftsresultat$374,9 mill.
FCF$835,2 mill.

Seoulin Bioscience maintains a strong liquidity position, with a current ratio of 3.56, indicating the company can easily cover its short-term liabilities with its current assets. The company's liq…

Dilution: Low · Liquidity: Low
058110KOSDAQ

058110.Kq

Advanced Medical Equipment & Technology
Kurs$2045.00
Børsverdi$31,69 mrd.
P/E
Omsetning$11,29 mrd.
Driftsresultat-$2,79 mrd.
FCF-$1,54 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 0.44, indicating a relatively conservative leverage position compared to the industry median of 0.65. However, the comp…

Dilution: Low · Liquidity: Medium
078160KOSDAQ

Medipost Co Ltd

Biotechnology & Medical Research
Kurs$13150.00
Børsverdi$513,98 mrd.
P/E
Omsetning$73,66 mrd.
Driftsresultat-$83,17 mrd.
FCF-$83,28 mrd.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.19, indicating a conservative leverage profile. With a current ratio of 1.33, Medipost maintains sufficient short…

Dilution: Low · Liquidity: Low
084110KOSDAQ

Huons Global Co Ltd

Pharmaceuticals
Kurs$35500.00
Børsverdi$433,21 mrd.
P/E15,0
Omsetning$847,45 mrd.
Driftsresultat$93,63 mrd.
FCF$54,80 mrd.

Huons Global maintains a strong liquidity position with KRW 193.2 billion in cash and equivalents, but its long-term debt of KRW 312.5 billion results in a net cash deficit. The company's liquidity…

Dilution: Low · Liquidity: Medium
0858HKEX

Extrawell Pharmaceutical Holdings Ltd

Pharmaceuticals
KursHK$0.07
BørsverdiHK$214,6 mill.
P/E
Omsetning
Driftsresultat
FCF
Dilution: Low · Liquidity: Unknown
0950HKEX

0950.Hk

Pharmaceuticals
KursHK$1.06
Børsverdi
P/E
OmsetningHK$1,44 mrd.
DriftsresultatHK$86,0 mill.
FCF-HK$53,0 mill.

The company maintains a relatively strong liquidity position, with a current ratio of 1.03, indicating that it can cover its short-term liabilities with its short-term assets. However, the free cas…

Dilution: Low · Liquidity: Medium
1134HKEX

1134.Hk

Medical Equipment, Supplies & Distribution
KursHK$0.35
Børsverdi
P/E
OmsetningHK$500,3 mill.
Driftsresultat-HK$11,1 mill.
FCF

The company's capital structure is characterized by a low debt-to-equity ratio of 0.06, indicating a conservative leverage position. However, the current ratio of 1.91 suggests moderate liquidity,…

Dilution: Low · Liquidity: Medium
140610.KN

140610.Kn

Pharmaceuticals
Kurs$13180.00
Børsverdi
P/E
Omsetning$25,1 mill.
Driftsresultat-$7,19 mrd.
FCF-$4,92 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing. However, its liquidity position is constrained, with a current…

Dilution: Low · Liquidity: Medium
175250KOSDAQ

175250.Kq

Pharmaceuticals
Kurs$2170.00
Børsverdi
P/E
Omsetning$83,38 mrd.
Driftsresultat-$24,40 mrd.
FCF-$34,01 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 1.17, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…

Dilution: Low · Liquidity: Medium
1777TPEx

SYN-Tech Chem & Pharm Co Ltd

Pharmaceuticals
Kurs$70.70
Børsverdi
P/E
Omsetning$269,8 mill.
Driftsresultat$74,4 mill.
FCF$82,9 mill.

SYN-Tech Chem & Pharm Co Ltd maintains a strong liquidity position, with a current ratio of 2.69 and cash and equivalents amounting to TWD 403.07 million, which represents 14.2% of total assets. Th…

Dilution: Low · Liquidity: Low
180400KOSDAQ

180400.Kq

Biotechnology & Medical Research
Kurs$2570.00
Børsverdi
P/E
Omsetning$29,36 mrd.
Driftsresultat-$25,90 mrd.
FCF-$30,53 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 103,434,353,530, significantly exceeding its total liabilities of KRW 60,928,994,740. The current ratio…

Dilution: Low · Liquidity: Low
190ATokyo Stock Exchange

190a.T

Biotechnology & Medical Research
Kurs¥97.00
Børsverdi
P/E
Omsetning
Driftsresultat-¥1,80 mrd.
FCF-¥1,79 mrd.

190A.T maintains a strong liquidity position, with cash and equivalents amounting to ¥2.55 billion, significantly exceeding its total liabilities of ¥244.34 million, resulting in a current ratio of…

Dilution: Low · Liquidity: Low
203400KOSDAQ

Abion Inc

Biotechnology & Medical Research
Kurs$2030.00
Børsverdi
P/E
Omsetning$880,1 mill.
Driftsresultat-$21,02 mrd.
FCF-$28,83 mrd.

Abion Inc maintains a strong liquidity position with KRW 34,369,645,560 in cash and equivalents, representing 42.6% of total assets. The company's debt-to-equity ratio of 0.13 indicates a conservat…

Dilution: Low · Liquidity: Low
2135HKEX

2135.Hk

Healthcare Facilities & Services
KursHK$0.12
Børsverdi
P/E
OmsetningHK$189,4 mill.
DriftsresultatHK$3,4 mill.
FCFHK$8,2 mill.

The company maintains a debt-to-equity ratio of 0.55, indicating a moderate level of leverage, and a current ratio of 0.77, suggesting potential liquidity constraints. Free cash flow stands at 8.22…

Dilution: Low · Liquidity: Medium
2189HKEX

2189.Hk

Healthcare Facilities & Services
KursHK$0.45
BørsverdiHK$450,0 mill.
P/E21,5
OmsetningHK$317,1 mill.
DriftsresultatHK$46,7 mill.
FCFHK$30,6 mill.

The company maintains a market capitalization of HKD 470 million and a price-to-earnings ratio of 21.48, indicating a moderate valuation relative to its earnings. Its price-to-book ratio of 1.08 su…

Dilution: Low · Liquidity: Medium
2370Tokyo Stock Exchange

Medinet Co Ltd

Biotechnology & Medical Research
Kurs¥26.00
Børsverdi¥7,25 mrd.
P/E
Omsetning¥151,5 mill.
Driftsresultat-¥364,8 mill.
FCF

Medinet Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to ¥4.9 billion, representing 80% of total assets. The company's liquidity FPT score indicates a low liquid…

Dilution: Low · Liquidity: Low
238120KOSDAQ

Aligned Genetics Inc

Advanced Medical Equipment & Technology
Kurs$3305.00
Børsverdi
P/E
Omsetning$3,19 mrd.
Driftsresultat$201,1 mill.
FCF$772,1 mill.

Aligned Genetics Inc maintains a strong liquidity position, with a current ratio of 4.24, indicating the company can easily cover its short-term liabilities with its current assets. The company's c…

Dilution: Low · Liquidity: Medium
246960KOSDAQ

SCL Science Inc

Pharmaceuticals
Kurs$1731.00
Børsverdi
P/E
Omsetning$1,13 mrd.
Driftsresultat-$542,7 mill.
FCF-$797,4 mill.

SCL Science Inc has a liquidity position that is below the industry median, with a current ratio of 2.44 and a negative net cash position after subtracting total debt. The company's cash and equiva…

Dilution: Low · Liquidity: Medium
300436Shenzhen Stock Exchange

Fujian Cosunter Pharmaceutical Co Ltd

Pharmaceuticals
Kurs$117.50
Børsverdi
P/E
Omsetning$416,4 mill.
Driftsresultat-$228,4 mill.
FCF-$223,6 mill.

Fujian Cosunter Pharmaceutical Co Ltd exhibits a weak capital structure and liquidity position, with a debt-to-equity ratio of 1.64 and a current ratio of 1.08, indicating limited short-term liquid…

Dilution: Low · Liquidity: Medium
300869Shenzhen Stock Exchange

Contec Medical Systems Co Ltd

Advanced Medical Equipment & Technology
Kurs$12.34
Børsverdi$4,96 mrd.
P/E
Omsetning$468,0 mill.
Driftsresultat-$26,5 mill.
FCF-$157,3 mill.

Contec Medical Systems Co Ltd has a market price of 11.79 CNY, with a market capitalization of 4.74 billion CNY. The company's price-to-book ratio is 2.73, and its price-to-tangible-book ratio is a…

Dilution: Low · Liquidity: Medium
3373TPEx

3373.Two

Medical Equipment, Supplies & Distribution
Kurs$16.80
Børsverdi
P/E
Omsetning$387,6 mill.
Driftsresultat-$70,4 mill.
FCF-$45,7 mill.

3373.TWO has a strong liquidity position, with a current ratio of 9.69, indicating that the company holds significantly more current assets than current liabilities. The company maintains no long-t…

Dilution: Low · Liquidity: Low
383930KOSDAQ

383930.Kq

Healthcare Facilities & Services
Kurs$2550.00
Børsverdi$32,60 mrd.
P/E
Omsetning$47,75 mrd.
Driftsresultat-$5,74 mrd.
FCF-$8,40 mrd.

The company's capital structure is characterized by a debt-to-equity ratio of 1.44, indicating a relatively high level of leverage. Its liquidity position is assessed as medium, with a current rati…

Dilution: Low · Liquidity: Medium
3869HKEX

3869.Hk

Healthcare Facilities & Services
KursHK$3.41
Børsverdi
P/E
OmsetningHK$1,47 mrd.
DriftsresultatHK$121,3 mill.
FCF

The company maintains a liquidity position with a current ratio of 1.62, indicating a moderate ability to meet short-term obligations. However, the debt-to-equity ratio of 2.1 suggests a relatively…

Dilution: Low · Liquidity: Medium
4107TPEx

Bioteque Corp

Medical Equipment, Supplies & Distribution
Kurs$113.50
Børsverdi$7,87 mrd.
P/E14,8
Omsetning$2,14 mrd.
Driftsresultat$670,3 mill.
FCF$302,8 mill.

Bioteque Corp maintains a strong capital structure with a debt-to-equity ratio of 0.17, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as…

Dilution: Low · Liquidity: Medium
4121TPEx

Rossmax International Ltd

Medical Equipment, Supplies & Distribution
Kurs$13.70
Børsverdi
P/E
Omsetning$951,4 mill.
Driftsresultat$4,2 mill.
FCF$65,3 mill.

Rossmax International Ltd maintains a relatively balanced capital structure, with total equity of TWD 15.54 billion and total liabilities of TWD 30.07 billion, resulting in a debt-to-equity ratio o…

Dilution: Low · Liquidity: Medium
4167TPEx

Savior Lifetec Corp

Pharmaceuticals
Kurs$19.15
Børsverdi
P/E
Omsetning$1,20 mrd.
Driftsresultat$182,2 mill.
FCF$356,5 mill.

Savior Lifetec Corp maintains a strong liquidity position, with a current ratio of 11.06, indicating a high ability to meet short-term obligations. The company holds TWD 588 million in cash and equ…

Dilution: Low · Liquidity: Low
4171TPEx

GeneReach Biotechnology Corp

Pharmaceuticals
Kurs$17.75
Børsverdi
P/E
Omsetning$45,9 mill.
Driftsresultat-$45,3 mill.
FCF-$4,9 mill.

GeneReach Biotechnology Corp has a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure. However, the company reported negative operating cash flow of -461,000 TWD a…

Dilution: Low · Liquidity: Medium
4186TPEx

4186.Two

Biotechnology & Medical Research
Kurs$10.45
Børsverdi
P/E
Omsetning$364,8 mill.
Driftsresultat
FCF

4186.TWO has a debt-to-equity ratio of 0.87, indicating a relatively balanced capital structure with a moderate reliance on debt financing. The company holds cash and equivalents of TWD 140.7 milli…

Dilution: Low · Liquidity: Medium
4192TPEx

4192.Two

Biotechnology & Medical Research
Kurs$20.00
Børsverdi
P/E
Omsetning$27,0 mill.
Driftsresultat-$47,2 mill.
FCF-$28,6 mill.

4192.TWO maintains a strong liquidity position, with a current ratio of 21.37, indicating a significant excess of current assets over current liabilities. The company holds TWD 157,334,000 in cash…

Dilution: Low · Liquidity: Low
432980KOSDAQ

432980.Kq

Pharmaceuticals
Kurs$2945.00
Børsverdi$23,78 mrd.
P/E27,7
Omsetning$20,80 mrd.
Driftsresultat$276,7 mill.
FCF$1,22 mrd.

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 2,911,710,830, which is sufficient to cover its long-term debt of KRW 3,024,339,060. The liquidity FPT…

Dilution: Low · Liquidity: Medium
4598Tokyo Stock Exchange

4598.T

Pharmaceuticals
Kurs¥130.00
Børsverdi
P/E
Omsetning
Driftsresultat-¥1,71 mrd.
FCF-¥1,72 mrd.

The company's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to ¥338.8 million, which significantly exceeds its total liabilities of ¥156.5 m…

Dilution: Low · Liquidity: Low